Every government that operates a public health system answers the same question: what do we pay for, and why? The mechanisms - HTA, tariff schedules, reimbursement codes - are treated as objective and evidence-based. They are none of these things.
The inputs - clinical trial evidence, utility metrics, comparator selections, outcome measures - were built on a male-default foundation. The required fixes are overwhelmingly methodological, not budgetary.
The Universal QALY Problem
The Utility Measurement Bias: EQ-5D measures 5 dimensions. Women with chronic conditions adapt their self-assessment downward. A woman with decade-long pelvic pain rates it 3/5 because she has normalized it. The result: treatments for conditions with long diagnostic delay appear to have unfavorable cost-per-QALY ratios because baseline utility is inflated by normalization (Ferreira et al., 2021; Whitehurst et al., 2014).
The Morbidity Penalty: QALYs privilege mortality reduction over morbidity reduction. Women live longer but spend ~25% more of their lives in poor health. Treatments for endometriosis, PCOS, or CVD in women are deemed "less valuable" because women are not dying from these conditions in the short term.
The Prevalence Penalty: Common conditions are forced into low price points. ICER issued an "Affordability Alert" for elagolix (endometriosis) because treating all eligible patients would exceed $915M/year - punishing the disease for being prevalent.
Country-by-Country Bias Entry Points
🇨🇭 Switzerland - WZW, TARDOC, EFAS
🇦🇺 Australia - PBAC, PBS
🇫🇮 Finland - HILA, Kela
🇺🇸 United States - The QALY Ban
Every Target Country Has an Open Window
| Country | Reform | Timeline | Window |
|---|---|---|---|
| Switzerland | TARDOC replacing TARMED | January 2026 | Fee values being set now |
| Switzerland | EFAS unified financing | Acute 2028 | New quality metrics from inception |
| Switzerland | Human Research Act revision | Due end 2026 | Sex-disaggregated evidence requirements |
| Australia | MBS reform (60+ min GP items) | 2025-26 | Expand to additional conditions |
| Finland | Yleistuki general benefit | May 2026 | Diagnostic screening integration |
| US/NYS | RAISE Act / DIGIT | March 2026 | Sex-specific AI governance criteria |
| Denmark | Women's Health Research Centre | DKK 160M, 2026 | Methodology partnerships |
For Decision-Makers
Every reform window that closes without sex-specific methodology locks in 20-30 years of suboptimal decisions. Action: Add sex-disaggregated evidence requirements, diagnostic-delay metrics, and pathway-specific utility adjustments to the next HTA methods consultation.
Your actuarial models have blind spots generating failure demand. Action: Run one retrospective formulary review on a female-prevalent condition using sex-stratified cost-effectiveness assumptions.
Conditions comprising ~14% of women's disease burden receive <1% of research funding (WEF/McKinsey/WHIT). Market opportunity: $46B current, >$100B addressable (BCG, 2025). Action: Build one payer-ready dossier with sex-stratified outcomes and time-to-diagnosis impact.
Request a Reimbursement Readiness Scan
A decision-ready memo showing where sex bias enters the pathway and what methodological changes are most defensible.
Contact FemTechnology →Sources & Evidence Base
All statistics in this analysis are sourced from peer-reviewed literature, government statistical offices, or published claims datasets. Key references:
- WEF/McKinsey Health Institute 2024 - $1T+ GDP opportunity
- Westergaard D et al., Nat Commun 2019 - DOI: 10.1038/s41467-019-08475-9
- Faubion SS et al., Mayo Clin Proc 2023 - DOI: 10.1016/j.mayocp.2023.02.025
- Felder S & Werblow A - Swiss MCL analysis: 3.5x cost disparity